Special Issue

Emerging Molecular and Translational Insights into Obstructive Sleep Apnea and Its Cardiovascular Comorbidities

Message from the Guest Editors

Obstructive Sleep Apnea (OSA) is increasingly being recognized as a systemic disorder associated with cardiovascular, metabolic, and neurocognitive consequences. Among these, its close relationship with atrial fibrillation (AF) and other cardiac arrhythmias highlights the interplay between sleep physiology, autonomic regulation, and molecular remodeling. This Special Issue aims to showcase recent advances regarding the pathophysiological mechanisms, diagnostic innovations, and therapeutic strategies of OSA and its cardiovascular comorbidities. Topics include molecular mechanisms, epigenetic and transcriptomic regulation, biomarkers, inflammation, oxidative stress, and endothelial dysfunction. We particularly welcome studies exploring translational applications of omics, artificial intelligence, and precision medicine to improve OSA diagnosis, risk stratification, and treatment outcomes. Multidisciplinary research that bridges molecular biology, clinical practice, and digital innovation is encouraged.

Guest Editors

Dr. Hui-Ting Wang

1. Emergency Department, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833401, Taiwan
2. School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung 804201, Taiwan

Dr. Yunglung Chen

Department of Cardiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Deadline for manuscript submissions

30 June 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/262003

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).